加倍下注:双难治性慢性淋巴细胞白血病临床管理的新协议
综述讨论双难治性慢性淋巴细胞白血病(对共价BTK抑制剂和BCL-2抑制剂维奈克拉均耐药)的治疗挑战,汇总非共价BTK抑制剂pirtobrutinib和CD19 CAR-T细胞疗法lisocabtagene maraleucel获美国FDA批准用于≥2线治疗后进展(包括共价BTK抑制剂和BCL-2抑制剂)患者的证据,以及新型BTK靶向疗法和T细胞衔接双特异性抗体在早期试验中的 promising 应答,并提出整合这些新药的创新治疗策略。
要点
- 双难治性CLL指对共价BTK抑制剂和维奈克拉均耐药,治疗选择有限。
- Pirtobrutinib和lisocabtagene maraleucel获FDA批准用于≥2线治疗后进展(含共价BTK抑制剂和BCL-2抑制剂)的CLL患者。
- 新型BTK靶向疗法和T细胞衔接双特异性抗体在经治CLL早期试验中显示 promising 应答。
核心结论
- 综述提出整合新型非共价BTK抑制剂、CD19 CAR-T细胞疗法、新型BTK靶向疗法和双特异性抗体的创新策略用于双难治性CLL,同时需考虑新疗法和临床试验可及性的差异。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- Pirtobrutinib和lisocabtagene maraleucel均获美国FDA批准用于≥2线治疗后进展(包括共价BTK抑制剂和BCL-2抑制剂)的CLL患者。
- 新型BTK靶向疗法和T细胞衔接双特异性抗体在经治CLL早期临床试验中取得 promising 应答。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted therapy with covalent Bruton tyrosine kinase inhibitors (cBTKis) and/or the B-cell lymphoma 2 inhibitor (BCL-2i) venetoclax is now well established in the first-line management of chronic lymphocytic leukemia (CLL). However, patients with "double-refractory" disease due to the acquired resistance to both drug classes represent an increasing clinical challenge for whom few well-tolerated and effective treatment options currently exist. The highly selective, noncovalent BTKi pirtobrutinib and CD19-directed chimeric antigen receptor T-cell therapy lisocabtagene maraleucel have both recently gained US Food and Drug Administation approval for use in patients with CLL, which has progressed following ≥2 prior lines, including a cBTKi and a BCL-2i. Additionally, novel BTK-directed therapies and T-cell-engaging bispecific antibodies have achieved promising responses in pretreated CLL in early-phase clinical trials. Here, we review the mechanisms responsible for resistance to cBTKi and venetoclax in CLL, appraise recent evidence supporting the use of each of the novel and emerging agent classes, and then suggest innovative treatment strategies incorporating these in patients with double-refractory disease, remaining cognizant of the variability of access to novel therapies and clinical trials.
引用
- Grainger BT, Thompson PA, Cheah CY, et al. Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia. Blood. 2025. PMID: 40209064. doi:10.1182/blood.2024024893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。